IXICO (PHYOF) ROE % Adjusted to Book Value: -44.20% (As of Mar. 2026)

IXICO PHYOF -53.33% 42 ROE % Adjusted to Book Value is -44.20% as of Mar. 2026. GuruFocus rates PHYOF with a GF Score™ of 42/100 and a GF Value™ of $0.07. The stock has 2 warning signs investors should review.

IXICO's ROE % for the quarter that ended in Mar. 2026 was -19.89%. IXICO's PB Ratio for the quarter that ended in Mar. 2026 was 0.45. IXICO's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -44.20%.

IXICO ROE % Adjusted to Book Value Related Terms

IXICO ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for IXICO's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IXICO ROE % Adjusted to Book Value Chart

IXICO Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

4.46

6.57

-15.15

-73.52

-38.34

IXICO Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-46.82	-45.59	-42.54	-28.78	-44.20

PHYOF vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, IXICO's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IXICO ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where IXICO's ROE % Adjusted to Book Value falls into.

Save Embed

42GF Score

IXICO PLC PHYOF

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

IXICO ROE % Adjusted to Book Value Calculation

IXICO's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-15.72%	/	0.41
	=	-38.34%

IXICO's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-19.89%	/	0.45
	=	-44.20%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of -44.20% mean?

IXICO (PHYOF) has a ROE % Adjusted to Book Value of -44.20% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on IXICO and its competitors.

Is IXICO's ROE % Adjusted to Book Value too high?

IXICO's current ROE % Adjusted to Book Value is -44.20%. Overall, IXICO has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.

How does IXICO's ROE % Adjusted to Book Value compare to VRTX and REGN?

IXICO's ROE % Adjusted to Book Value of -44.20% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on IXICO and its competitors. IXICO's current ROE % Adjusted to Book Value is -44.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is IXICO stock overvalued right now?

IXICO (PHYOF) has a current ROE % Adjusted to Book Value of -44.20%. The stock's GF Value™ is $0.07, compared to a current price of $0.07 — trading right at its estimated fair value. The current ROE % Adjusted to Book Value is -44.20%. IXICO's overall GF Score™ is 42/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For IXICO (PHYOF), the current ROE % Adjusted to Book Value is -44.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IXICO (PHYOF) Overvalued in 2026?

Based on GuruFocus' analysis, IXICO stock appears to be undervalued. The current stock price of $0.07 is trading 0% below its estimated GF Value™ of $0.07.

Key valuation signals for PHYOF:

ROE % Adjusted to Book Value: -44.20%
GF Value™: $0.07 vs. price of $0.07 (0% below fair value)
GF Score™: 42/100 with 2 warning signs

No single metric tells the full story. See the PHYOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IXICO Business Description

Industry Healthcare Biotechnology

Comparable Companies LSE:APTA LSE:FAB LSE:AREC LSE:CIZ LSE:SBTX LSE:GENF AQSE:PBX LSE:IMM LSE:OPTI LSE:CRTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges IXI:UK

Address 15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN

Website https://www.ixico.com

IXICO PLC provides neuroscience imaging and biomarker analytics services, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. It operates as an imaging contract research organization, supporting clinical trials for neurological disorders by processing and analyzing imaging data. Its platform is used to measure biomarkers associated with diseases such as Alzheimer's, Huntington's, and Parkinson's.

42GF Score

Get the complete analysis for PHYOF

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07

Price